Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-04-24
1995-10-24
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 514934, 4242291, 4242301, 4242311, A61K 3816, A61K 3818
Patent
active
054610290
ABSTRACT:
The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins. Both HBNF and MK possess heparin-binding activity, displace bFGF from high affinity receptors and inhibit growth of endothelial cells.
REFERENCES:
patent: 5210026 (1993-05-01), Kovesdi et al.
Tomomura, M., et al. (1990) Biochem. Biophys. Res. Comm. 171:603-609.
Raurala, H. (1989) EMBO J. 8: 2933-2941.
WuDunn, D., et al. (1989) J. Virol. 63:52-58.
Kovesdi, I. et al. (1990) Biochem. Biophys. Res. Comm. 172: 850-854.
Kretschmer, P. J., et al. (1991) Growth Factors 5: 99-114.
Hirsch, M. S. et al. (1987) Scientific American 256(4): 66-75.
Kaner, R. J., et al. (1990) Science 248: 1410-1413.
Receptor-and heparin-binding domains of basic fibroblast growth factor, P.N.A.S. vol. 85: 2324-2328 (Apr. 1988).
Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for heparin, Eur. J. Bioch., vol. 188: 239-245 (1990) Seno, M. et al.
Backer Joseph M.
Ostrander Michael R.
American Cyanamid Company
Draper Garnette D.
Fitzgerald David L.
LandOfFree
Method of treating herpes viral infections using HBNF and MK pro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating herpes viral infections using HBNF and MK pro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating herpes viral infections using HBNF and MK pro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886635